2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2019
Working in Recovery: A Medical Student’s Experience
Neustadter E. Working in Recovery: A Medical Student’s Experience. Psychiatric Services 2019, 70: 853-854. PMID: 31337327, DOI: 10.1176/appi.ps.701001.Commentaries, Editorials and Letters
2017
Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions
Fineberg SK, Leavitt J, Landry CD, Neustadter ES, Lesser RE, Stahl DS, Deutsch-Link S, Corlett PR. Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions. Psychiatry Research 2017, 260: 384-390. PMID: 29248760, PMCID: PMC5972044, DOI: 10.1016/j.psychres.2017.11.054.Peer-Reviewed Original Research
2015
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies
Goldstein D, Zeichner S, Bartnik C, Neustadter E, Flowers C. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clinical Colorectal Cancer 2015, 15: 1-6. PMID: 26541320, PMCID: PMC4744531, DOI: 10.1016/j.clcc.2015.10.002.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinCetuximabColorectal NeoplasmsCost-Benefit AnalysisDrug CostsFluorouracilHumansIrinotecanLeucovorinNeoplasm MetastasisOrganoplatinum CompoundsOxaliplatinPanitumumabQuality-Adjusted Life YearsTreatment OutcomeUnited StatesConceptsMetastatic colorectal cancerCurrent treatment strategiesTreatment strategiesSystematic reviewIncremental cost-effectiveness ratioUS payer perspectiveHigher drug costsCost-effectiveness ratioCost-effective treatmentCost-effectiveness analysisColorectal cancerCurrent therapiesHigh-value treatmentsPayer perspectiveDrug costsVEGF pathwayUS FoodDrug AdministrationOlder agentsModern agentsSearch criteriaTreatmentPanitumumabCetuximabIrinotecan
2014
Is Prevention a Realistic Goal for Schizophrenia?
Kohler C, Borgmann-Winter K, Hurford I, Neustadter E, Yi J, Calkins M. Is Prevention a Realistic Goal for Schizophrenia? Current Psychiatry Reports 2014, 16: 439. PMID: 24566772, DOI: 10.1007/s11920-014-0439-y.Peer-Reviewed Original ResearchConceptsEarly clinical symptomsOnset of psychosisCertain clinical presentationsLarge epidemiological studiesClinical presentationClinical symptomsClinical riskEpidemiological studiesSchizophrenia phenotypePsychosisMultidisciplinary approachRisk stateSchizophreniaRealistic goalsRecent studiesOnsetSymptomsPrevention